Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 7/20 | 0.49 |
| ▸ | NNMT | P40261 | 2/20 | 0.49 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.45 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.38 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6132335 | 0.93 | NNMT (0.52) | OXTRNNMTMKNK1MKNK2LMNA | |
| SCHEMBL6682866 | 0.89 | OXTR (0.48) | OXTRNNMTMKNK1MKNK2LMNA | |
| SCHEMBL6681336 | 0.86 | MEN1 (0.54) | OXTRPARP10MAOBKMT2A | |
| SCHEMBL4027589 | 0.86 | CA1 (0.51) | LMNACA1CA2PARP10PARP1 | |
| SCHEMBL6132418 | 0.75 | CA1 (0.49) | LMNACA1CA2PARP10PARP1 | |
| SCHEMBL19211861 | 0.71 | OXTR (0.48) | OXTRNNMTMKNK1MKNK2LMNA | |
| SCHEMBL6539765 | 0.70 | NNMT (0.54) | NNMTMKNK1MKNK2LMNAMAPT | |
| SCHEMBL31676582 | 0.68 | PTGS2 (0.55) | CA1CA2MAPTHPGDMAOB | |
| SCHEMBL26036861 | 0.68 | NNMT (0.67) | OXTRNNMTMKNK1MKNK2 | |
| SCHEMBL29975550 | 0.67 | NNMT (1.00) | OXTRNNMTMKNK1MKNK2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6927230-B2 | Triazole derivatives | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-09 | — | — | US | disclosed |
| EP-1442026-A1 | TRIAZOLE DERIVATIVES AS CYCLOOXYGENASE (COX) INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-04 | — | — | EP | disclosed |
| US-20030191155-A1 | Triazole derivatives | ASTELLAS PHARMA INC. (JP) | 2003-10-09 | — | — | US | disclosed |
| WO-2003040110-A1 | TRIAZOLE DERIVATIVES AS CYCLOOXYGENASE (COX) INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030191155-A1 | Triazole derivatives | CBR1, CBR3, CYP1B1 | OXTR 242/4885NNMT 1684/4885MKNK1 3072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.